Lucid Diagnostics Q4 2023 Earnings Report $1.46 -0.03 (-2.01%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Lucid Diagnostics EPS ResultsActual EPS-$0.26Consensus EPS N/ABeat/MissN/AOne Year Ago EPS-$0.22Lucid Diagnostics Revenue ResultsActual Revenue$1.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALucid Diagnostics Announcement DetailsQuarterQ4 2023Date3/26/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptLUCD Earnings History Lucid Diagnostics Earnings HeadlinesLucid Diagnostics entered first concierge medicine contract with LEAA HealthFebruary 20 at 11:10 AM | markets.businessinsider.comLucid Diagnostics Executes First Concierge Medicine Contract with LEAA HealthFebruary 20 at 8:31 AM | prnewswire.comElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.February 22, 2025 | True Market Insiders (Ad)SI-BONE (NASDAQ:SIBN) & Lucid Diagnostics (NASDAQ:LUCD) Critical ComparisonFebruary 17, 2025 | americanbankingnews.comLucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head SurveyFebruary 16, 2025 | americanbankingnews.comLucid Diagnostics stock hits 52-week high at $1.5 amid growth optimismFebruary 14, 2025 | msn.comSee More Lucid Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lucid Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lucid Diagnostics and other key companies, straight to your email. Email Address About Lucid DiagnosticsLucid Diagnostics (NASDAQ:LUCD) operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.View Lucid Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
